Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Alcohols Stories

2013-12-10 23:34:35

New non-addictive opiate withdrawal supplement backed by scientific research and personal experiences starts working with the first dose. Boca Raton, Fla (PRWEB) December 10, 2013 With opiate addiction now a national epidemic, more people than ever are looking for a less painful way to detox, break the addiction cycle and move on with far happier lives. Today, Sunrise Nutraceuticals is pleased to announce the nationwide release of Elimidrol, a revolutionary new opiate withdrawal support...

2013-12-10 23:19:45

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked...

2013-12-06 12:22:40

DUBLIN, December 6, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/9wgk7v/cholic_acid_cas) has announced the addition of the "Cholic Acid (CAS 81-25-4) Market Research Report 2013" [http://www.researchandmarkets.com/research/9wgk7v/cholic_acid_cas ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Cholic Acid (CAS 81-25-4) Market Research Report 2013 presents comprehensive data on...

2013-12-06 12:22:27

DUBLIN, December 6, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fgz2cg/fusel_oil_cas) has announced the addition of the "Fusel Oil (CAS 8013-75-0) Market Research Report 2012" [http://www.researchandmarkets.com/research/fgz2cg/fusel_oil_cas ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The study Fusel Oil (CAS 8013-75-0) Market Research Report 2012' presents an overview of the...

2013-12-05 23:48:03

No data on patients with metformin intolerance or contraindication The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is needed, but the drug metformin is not tolerated or cannot be used. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency...

2013-12-05 08:29:22

SOCRATES compares ticagrelor versus aspirin for the prevention of major vascular events in patients with acute ischaemic stroke or transient ischaemic attack THEMIS compares ticagrelor versus placebo for the long-term prevention of major vascular events in patients with Type 2 diabetes at high cardiovascular risk MISSISSAUGA, ON, Dec. 5, 2013 /CNW/ - AstraZeneca has announced plans to conduct two new Phase IIIb clinical studies as part of PARTHENON, the company's largest...

2013-12-05 04:21:04

FDA Reclassification of Hydrocodone to Schedule II Could Boost Sales. PALO ALTO, CA, Dec. 5, 2013 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that work on the name change to Praxsyn Corporation is nearing completion and that the Company expects to be able to file a request with FINRA early next week along with filing the necessary filings and disclosures with the SEC and the State of Illinois. Furthermore, the audit of Mesa Pharmacy, Inc.'s...

2013-12-03 16:25:16

LONDON, Dec. 3, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, has announced that the initial findings of its clinical trial with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health, supports Lightlake's intranasal delivery of naloxone as a promising innovative treatment for opioid overdose....

2013-12-03 08:33:07

STAMFORD, Conn., Dec. 3, 2013 /PRNewswire/ -- Purdue Pharma L.P. and Impax Laboratories, Inc. announced today that the companies have agreed to resolve the patent infringement lawsuits between them now pending in the United States District Court for the Southern District of New York concerning certain Purdue patents, including patents for abuse-deterrent technology, protecting OxyContin® (oxycodone HCl controlled-release) Tablets CII ("OxyContin"). According to the agreement, Purdue and...

2013-12-03 08:31:41

NORTHBROOK, Ill., Dec. 3, 2013 /PRNewswire/ -- Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and a five-year extension of market exclusivity if a product receiving such a designation is approved in the United States. These...